Skip to content

Study · Randomized controlled trial · n = 409 · 2016

7 results

Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.

Mari A, Del Prato S, Ludvik B, Milicevic Z, de la Peña A, Shurzinske L, Karanikas CA, Pechtner V

Diabetes, obesity & metabolism16 May 2016Cited by 16 (Europe PMC)

PMID27059816 (opens in a new tab)DOI10.1111/dom.12671 (opens in a new tab)PepBankPUB-27059816
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialMechanism

    Insulin sensitivity increased less with dulaglutide than with metformin.

    In plain wordsInsulin sensitivity improved less with dulaglutide than with metformin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInsulin sensitivity
    Study

    n = 409

    Comparator
    Metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Insulin sensitivity increased more with metformin versus dulaglutide.
    2 context sentences
    Summary · context
    This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes.
    Summary · context
    Meals were administered at baseline, 26 and 52 weeks to patients randomized to monotherapy with dulaglutide 1.5 mg/week (n = 133), dulaglutide 0.75 mg/week (n = 136), or metformin ≥1500 mg/day (n = 140).
  2. 02HumanRandomized controlled trialMechanism

    Beta-cell function increased with dulaglutide 0.75 mg and remained unchanged with metformin.

    In plain wordsDulaglutide 0.75 mg improved insulin-producing cell function, while metformin showed no change.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBeta-cell function
    Study

    n = 276

    Comparator
    Metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg/weekAs given in this study (human).

    Source sentences

    Summary
    β-cell function [AUCinsulin /AUCglucose (0-3 h)] increased with dulaglutide and was unchanged with metformin (p ≤ 0.005, both doses).
    2 context sentences
    Summary · context
    This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes.
    Summary · context
    Meals were administered at baseline, 26 and 52 weeks to patients randomized to monotherapy with dulaglutide 1.5 mg/week (n = 133), dulaglutide 0.75 mg/week (n = 136), or metformin ≥1500 mg/day (n = 140).
  3. 03HumanRandomized controlled trialMechanism

    Beta-cell function increased with dulaglutide 1.5 mg and remained unchanged with metformin.

    In plain wordsDulaglutide 1.5 mg improved insulin-producing cell function, while metformin showed no change.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBeta-cell function
    Study

    n = 273

    Comparator
    Metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg/weekAs given in this study (human).

    Source sentences

    Summary
    β-cell function [AUCinsulin /AUCglucose (0-3 h)] increased with dulaglutide and was unchanged with metformin (p ≤ 0.005, both doses).
    2 context sentences
    Summary · context
    This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes.
    Summary · context
    Meals were administered at baseline, 26 and 52 weeks to patients randomized to monotherapy with dulaglutide 1.5 mg/week (n = 133), dulaglutide 0.75 mg/week (n = 136), or metformin ≥1500 mg/day (n = 140).
  4. 04HumanRandomized controlled trialMechanism

    Dulaglutide 0.75 mg improved insulin secretion rate at 9 mmol/l glucose in patients with type 2 diabetes.

    In plain wordsDulaglutide 0.75 mg improved insulin release during the meal test.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseInsulin secretion rate
    Study

    n = 136

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg/weekAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide improved insulin secretion rate at 9 mmol/l glucose (p ≤ 0.04, both doses) and β-cell glucose sensitivity (p = 0.004, dulaglutide 1.5 mg).
    2 context sentences
    Summary · context
    This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes.
    Summary · context
    Meals were administered at baseline, 26 and 52 weeks to patients randomized to monotherapy with dulaglutide 1.5 mg/week (n = 133), dulaglutide 0.75 mg/week (n = 136), or metformin ≥1500 mg/day (n = 140).
  5. 05HumanRandomized controlled trialMechanism

    Dulaglutide 1.5 mg improved insulin secretion rate at 9 mmol/l glucose in patients with type 2 diabetes.

    In plain wordsDulaglutide 1.5 mg improved insulin release during the meal test.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseInsulin secretion rate
    Study

    n = 133

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg/weekAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide improved insulin secretion rate at 9 mmol/l glucose (p ≤ 0.04, both doses) and β-cell glucose sensitivity (p = 0.004, dulaglutide 1.5 mg).
    2 context sentences
    Summary · context
    This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes.
    Summary · context
    Meals were administered at baseline, 26 and 52 weeks to patients randomized to monotherapy with dulaglutide 1.5 mg/week (n = 133), dulaglutide 0.75 mg/week (n = 136), or metformin ≥1500 mg/day (n = 140).
  6. 06HumanRandomized controlled trialMechanism

    Dulaglutide 1.5 mg improved beta-cell glucose sensitivity in patients with type 2 diabetes.

    In plain wordsDulaglutide 1.5 mg improved how insulin-producing cells responded to glucose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBeta-cell glucose sensitivity
    Study

    n = 133

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg/weekAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide improved insulin secretion rate at 9 mmol/l glucose (p ≤ 0.04, both doses) and β-cell glucose sensitivity (p = 0.004, dulaglutide 1.5 mg).
    2 context sentences
    Summary · context
    This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes.
    Summary · context
    Meals were administered at baseline, 26 and 52 weeks to patients randomized to monotherapy with dulaglutide 1.5 mg/week (n = 133), dulaglutide 0.75 mg/week (n = 136), or metformin ≥1500 mg/day (n = 140).

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 07HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome

    Post-meal glucose AUC decreased similarly across dulaglutide and metformin groups at 26 weeks.

    In plain wordsBlood sugar after meals decreased similarly with dulaglutide and metformin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePost-meal glucose AUC
    Study

    n = 409

    Comparator
    Metformin
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    At 26 weeks, similar decreases in area under the curve for glucose [AUCglucose (0-3 h)] were observed among all groups.
    2 context sentences
    Summary · context
    This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes.
    Summary · context
    Meals were administered at baseline, 26 and 52 weeks to patients randomized to monotherapy with dulaglutide 1.5 mg/week (n = 133), dulaglutide 0.75 mg/week (n = 136), or metformin ≥1500 mg/day (n = 140).

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.